Tyra co-founders Todd Harris (L) and Daniel Bensen
Why do some targeted cancer therapies stop working? For Tyra, that's the $106M question
Targeted cancer therapies can be quite effective. Until, for some patients, the cancer mutates, and the treatment stops working.
“It’s not unlike resistance in antibiotics …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.